Drug intelligence / Profile preview

clonidine + methylphenidate

Development stage: Unknown
Lead developer: Tris Pharma
Modality: Small Molecules
Administration: Oral

Overview

A combination of clonidine, an alpha-2 adrenergic receptor agonist, and methylphenidate, a central nervous system stimulant. This combination is used primarily for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), particularly when either medication alone doesn't provide complete symptom relief. Clonidine helps control attention and hyperactivity by increasing norepinephrine in the brain, while methylphenidate works by increasing dopamine levels.

Targets

SERT (Sodium-dependent serotonin transporter)ADRA2C (α2C)ADRA1A (α1A)ADRA2A (α2A)ADRA2B (α2B)IR (Imidazoline receptor)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on clonidine + methylphenidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clonidine + methylphenidate.

Explore the full profile